Could new US investment curbs complicate China’s biotech licensing surge?
New restrictions from the US Treasury Department aim to limit direct US investment and joint ventures for Chinese biotech firms.
Quick Look
The US Treasury Department released draft rules under Treasury Secretary Scott Bessent to place Chinese biotech firms under greater investment scrutiny.
AI-generated summary
Why It Matters
US Treasury Department draft rules expand outbound investment screening programmes to include biotechnology for countries of concern.
The US Treasury Department’s draft rules released last week would “make it much harder for Chinese biotech firms to attract direct US investment or enter joint ventures”, according to David Zhang, an analyst at policy research firm Trivium China.
US Treasury Secretary Scott Bessent added biotechnology to an outbound investment screening programme, placing a broad range of transactions involving “countries of concern”, including China, under greater scrutiny.
Open Questions
- When will the draft rules be finalized?
- Which specific biotech firms will be impacted?







